feedback

Course Director

Jeffrey E. Lancet, MD
Jeffrey E. Lancet, MD

Moffitt Cancer Center
Tampa, Florida

Faculty

Robert J. Soiffer
Robert J. Soiffer, MD

Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Accredited by

The Medical College of Wisconsin

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2017-Apr-04
Expiration Date:2018-Apr-03
Estimated Time for Completion:1 hour
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

Hematopoietic stem cell transplant (HCT) clearly has a role in acute myeloid leukemia (AML) management, but one intriguing question on the future of HCT in AML concerns the rapid emergence of several novel and active therapeutic options. Newer therapies, including novel cytotoxic and targeted agents, may offer patients who struggle to benefit from conventional chemotherapy a chance for better outcomes, including in high-risk settings or in populations where the benefit of “7+3” is uneven at best. What will the validation of newer therapies mean for HCT-eligible patients with AML and for post-HCT outcomes? In this activity based on a recent live symposium held at the BMT Tandem Meetings in 2017, a panel of experts addresses this important question and offers clinical insight and new evidence that may define how HCT is used in conjunction with a range of next-generation therapies in the AML setting.

Upon completion of this activity, participants should be better able to:

  • Summarize the current role of HCT for transplant-eligible individuals with AML
  • Discuss evidence on the use of novel cytotoxic and/or targeted therapies in AML, including their impact on HCT-related outcomes
  • Develop strategies to maximize post-HCT outcomes in AML, including through the management of post-HCT complications

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, oncology transplant specialists, and other clinicians involved in the management of patients with acute myeloid leukemia.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: April 04, 2017 - April 03, 2018
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Jeffrey E. Lancet, MD
Senior Member
Department Chair - Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Jeffrey E. Lancet, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Baxalta; Bio-Path Holdings; BioSight; Celgene Corporation; Daiichi Sankyo, Inc.; Erytech Pharma; Janssen Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.

Faculty

Robert J. Soiffer, MD
Vice Chair, Department of Medical Oncology
Chief, Division of Hematologic Malignancies
Co-Chief, Stem Cell Transplantation
Institute Physician
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Robert J. Soiffer, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Gilead; Jazz Pharmaceuticals, Inc.; Juno Therapeutics; Kiadis Pharma; and Novartis Pharmaceuticals Corporation.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Providership

This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.